Bristol-Myers
Squibb Company (NYSE:BMY) today announced that its Board of
Directors has elected Thomas J. Lynch, Jr., M.D. to the Board, effective
January 1, 2014. Dr. Lynch will serve as a member of the Science and
Technology Committee of the Board of Directors.
Dr. Lynch, 53, is currently the director of the Yale Cancer Center and
physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven. He
is also the Richard Sackler and Jonathan Sackler Professor of Medical
Oncology at Yale-New Haven. He has held these positions since 2009. From
1993 to 2009, he was a professor of medicine at Harvard Medical School
and chief of hematology/oncology at Massachusetts General Hospital (MGH)
Cancer Center. He also served as director of the Center for Thoracic
Cancers at MGH and director of medical oncology at MGH Thoracic Oncology
Center.
“Tom is both a world class oncologist and a highly accomplished business
leader. As we advance our work in immuno-oncology and build our
leadership position in oncology, his guidance and scientific and
business perspectives will be invaluable,” said Lamberto
Andreotti, chief executive officer, Bristol-Myers Squibb.
James
M. Cornelius, chairman of Bristol-Myers Squibb, added, “We are very
pleased to have Tom join our Board. His rare combination of skills and
track record of success in both medicine and business uniquely qualify
him to serve on our Board of Directors.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Copyright Business Wire 2013